With new data a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

AvroBio believes new data could start to alleviate concerns about the durability of the one-time gene therapy that surfaced last fall and ravaged the biotech’s stock price.

More From BioPortfolio on "With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease"